PROTAGONIST THERAPEUTICS INC (PTGX)
US74366E1029 - Common Stock
PTGX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PTGX as it has an excellent financial health rating, but there are worries on the profitability. PTGX is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year PTGX has reported negative net income.
PTGX had a negative operating cash flow in the past year.
In the past 5 years PTGX always reported negative net income.
In the past 5 years PTGX always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -22.06%, PTGX is doing good in the industry, outperforming 79.15% of the companies in the same industry.
With an excellent Return On Equity value of -23.45%, PTGX belongs to the best of the industry, outperforming 84.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.06% | ||
| ROE | -23.45% | ||
| ROIC | N/A |
ROA(3y)-36.52%
ROA(5y)-35.95%
ROE(3y)-41.46%
ROE(5y)-48.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PTGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PTGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
PTGX has more shares outstanding than it did 1 year ago.
PTGX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 50.84 indicates that PTGX is not in any danger for bankruptcy at the moment.
PTGX's Altman-Z score of 50.84 is amongst the best of the industry. PTGX outperforms 97.61% of its industry peers.
There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 50.84 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
PTGX has a Current Ratio of 16.71. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
PTGX's Current ratio of 16.71 is amongst the best of the industry. PTGX outperforms 90.94% of its industry peers.
A Quick Ratio of 16.71 indicates that PTGX has no problem at all paying its short term obligations.
PTGX has a Quick ratio of 16.71. This is amongst the best in the industry. PTGX outperforms 90.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.71 | ||
| Quick Ratio | 16.71 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 42.69% over the past year.
PTGX shows a strong growth in Revenue. In the last year, the Revenue has grown by 125.73%.
Measured over the past years, PTGX shows a quite strong growth in Revenue. The Revenue has been growing by 14.17% on average per year.
EPS 1Y (TTM)42.69%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q163.77%
Revenue 1Y (TTM)125.73%
Revenue growth 3Y27.97%
Revenue growth 5Y14.17%
Revenue growth Q2QN/A
3.2 Future
PTGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.02% yearly.
The Revenue is expected to grow by 55.05% on average over the next years. This is a very strong growth
EPS Next Y151.38%
EPS Next 2Y20.34%
EPS Next 3Y-0.15%
EPS Next 5Y22.02%
Revenue Next Year281.25%
Revenue Next 2Y85.41%
Revenue Next 3Y97.67%
Revenue Next 5Y55.05%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
PTGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 40.16, which means the current valuation is very expensive for PTGX.
Based on the Price/Forward Earnings ratio, PTGX is valued cheaper than 92.65% of the companies in the same industry.
PTGX is valuated expensively when we compare the Price/Forward Earnings ratio to 20.20, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 40.16 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PTGX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.34%
EPS Next 3Y-0.15%
5. Dividend
5.1 Amount
PTGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROTAGONIST THERAPEUTICS INC
NASDAQ:PTGX (5/17/2024, 7:21:40 PM)
After market: 30.74 0 (0%)30.74
-1.2 (-3.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.80B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 40.16 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.06% | ||
| ROE | -23.45% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 16.71 | ||
| Quick Ratio | 16.71 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)42.69%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y151.38%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)125.73%
Revenue growth 3Y27.97%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y